logo-loader
viewZelira Therapeutics Ltd.

Zelda Therapeutics on track to report on multiple clinical trials

Snapshot

Zelda has released its December quarterly report confirming multiple trials are on track.

medicinal cannabis concept

Quick facts: Zelira Therapeutics Ltd.

Price: 0.056 AUD

ASX:ZLD
Market: ASX
Market Cap: $42.5 m
Follow

Zelda Therapeutics Ltd (ASX:ZLD) continues to progress its core clinical and pre-clinical activities focused on medicinal cannabis.

Importantly, it has also established the foundations to commercialise its medicinal cannabis products in the event the clinical programs are successful.

Zelda remains on-track to report on the outcome from its clinical trials for insomnia, autism and opioid reduction by mid-2019.

The company is also continuing to assess opportunities to expand its clinical programs where they align with its strategic objectives.

Finally, Zelda is progressing discussions with third parties aiming at securing agreements to distribute clinically-validated Zelda products globally.

READ: Zelda Therapeutics investing in medicinal cannabis oral spray

Zelda closed the December quarter with a cash position of $4.41 million and is forecasting expenditure of $1.4 million (including $980,000 on R&D) in the current March quarter.

The increase in R&D expenditure reflects an expansion to the company’s clinical trial activities and additional costs associated with management of its growing intellectual property portfolio.

Harry Karelis steps back from executive role, remains chairman

Zelda’s chairman Harry Karelis said: “This move marks a key step in Zelda’s strategic plan to position the company for success as it enters into the clinical trial and commercialisation phases of its development.

“With the recent appointment of Dr Richard Hopkins as managing director, along with key additions to our Medical Advisory Board and operational team, the time is right for me to step-back from the executive role, as we intended.

“In my ongoing role as chair, I will continue to work with my colleagues on the Zelda Board and the executive team to ensure we deliver on our key milestones.

“With a number of clinical trials underway and our path to commercialisation well advanced, this promises to be a transformational year for the company.”

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd. named herein, including the promotion by the Company of Zelira Therapeutics Ltd. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics on recent acquisition with Ilera

Zelira Therapeutics Ltd (ASX:ZLD) founder and chairman Osagie Imasogie and deputy chairman Harry Karelis speaks to Proactive on the recent acquisition of Ilera Therapeutics LLC.  Following overwhelming shareholder support, the merger will create a global medicinal cannabis company called...

1 week, 6 days ago

2 min read